Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T L Holyoake

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Leukemia|September 30, 2006
Human neutrophil elastase is not a target for therapy in chronic myeloid leukaemiaE K Allan, T L Holyoake, H G Jørgensen
Scottish Medical Journal|March 13, 2012
Smouldering systemic mastocytosis presenting with cryptic life-threatening crises: case report and literature reviewM Shah, T L Holyoake, B Jackson, et al.
Leukemia & Lymphoma|July 28, 2016
Acute Cardiotoxicity After Daunorubicin in Acute Myeloid LeukaemiaT L Holyoake, K J Hillan, N P Lucie
Hematology (Amsterdam, Netherlands)|July 14, 2016
CD34 Selection and EX Vivo Expansion of Haemopoietic Progenitor Cells: A Review of Laboratory MethodologyT L Holyoake, M J Alcorn, L J Richmond
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1996
The CD34 antigen: potential clinical advantages of CD34 selectionT L Holyoake, M J Alcorn, I M Franklin
Experimental Hematology|September 10, 1999
Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrowT L Holyoake, F E Nicolini, C J Eaves
Scottish Medical Journal|October 7, 2004
The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000S J Harrison, P R E Johnson, T L Holyoake
Cancer Immunology, Immunotherapy : CII|February 5, 2005
Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemiaM Copland, A R Fraser, S J Harrison, et al.
British Journal of Cancer|April 3, 2003
Is there a cloud in the silver lining for imatinib?S C Paterson, K D Smith, T L Holyoake, et al.
Leukemia|April 7, 2011
Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cellsE K Allan, T L Holyoake, A R Craig, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Leukemia|September 30, 2006
Human neutrophil elastase is not a target for therapy in chronic myeloid leukaemiaE K Allan, T L Holyoake, H G Jørgensen
Scottish Medical Journal|March 13, 2012
Smouldering systemic mastocytosis presenting with cryptic life-threatening crises: case report and literature reviewM Shah, T L Holyoake, B Jackson, et al.
Leukemia & Lymphoma|July 28, 2016
Acute Cardiotoxicity After Daunorubicin in Acute Myeloid LeukaemiaT L Holyoake, K J Hillan, N P Lucie
Hematology (Amsterdam, Netherlands)|July 14, 2016
CD34 Selection and EX Vivo Expansion of Haemopoietic Progenitor Cells: A Review of Laboratory MethodologyT L Holyoake, M J Alcorn, L J Richmond
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1996
The CD34 antigen: potential clinical advantages of CD34 selectionT L Holyoake, M J Alcorn, I M Franklin
Experimental Hematology|September 10, 1999
Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrowT L Holyoake, F E Nicolini, C J Eaves
Scottish Medical Journal|October 7, 2004
The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000S J Harrison, P R E Johnson, T L Holyoake
Cancer Immunology, Immunotherapy : CII|February 5, 2005
Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemiaM Copland, A R Fraser, S J Harrison, et al.
British Journal of Cancer|April 3, 2003
Is there a cloud in the silver lining for imatinib?S C Paterson, K D Smith, T L Holyoake, et al.
Leukemia|April 7, 2011
Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cellsE K Allan, T L Holyoake, A R Craig, et al.
Pageof 7